Skip to main content


Disease specificity

Traditional tests for immunologic diseases measure disease activity with non-specific injury markers, markers of fully evolved injury, or by measuring the disease agent itself. A need exists to predict whether an immunological disease will occur using tests that are highly specific for that disease.

Personalized risk assessment

Because of wide individual variation in immune response, thresholds of disease-risk or disease severity are unlikely to be the same in any two individuals. Therefore, predicting disease risk in individuals can be difficult with traditional tests. Disease-risk assessment may be most useful when it is specific to an individual and can be compared over time in that individual.

Advantages of cell-based assays

Personalized disease-risk assessment with cellular biomarkers utilizes the inherent attributes of cells.

  • Cells represent the first living unit to recognize potentially harmful foreign substances.
  • Cells are also the first living unit to respond, recruit other cells to respond, or retain memory to facilitate future inflammatory responses.
  • Plexision's cellular assays simulate disease and generate test outputs, which are normalized to the individual, enabling personalized disease-risk assessment.


Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.